Record lev­els of VC fi­nanc­ing and R&D boom left bio­phar­ma com­pa­nies clam­or­ing for space. How bad is it?

There are mul­ti­ple ways to mea­sure just how vi­brant the life sci­ence in­dus­try is: the in­flux of ven­ture cap­i­tal (now re­treat­ing slight­ly from a record high), the num­ber of new in­cu­ba­tors and star­tups and Big Phar­ma spin­offs (still go­ing strong de­spite slow­ing down), the M&A as well as part­ner­ship deals (mega­bil­lions in cash were ex­changed just last year), and so on. But one met­ric is par­tic­u­lar­ly help­ful if you want to track ac­tiv­i­ties on the ground, and that is re­al es­tate oc­cu­pan­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER